Fortis Health.

Why is Fortis Healthcare Ltd falling/rising?

As of 10-Jun, Fortis Healthcare Ltd's stock price is 989.05, down 0.14%. Despite a recent decline, the stock has outperformed the Sensex over multiple periods and maintains strong fundamentals, including low debt and healthy growth rates.

As of 10-Jun, Fortis Healthcare Ltd's stock price is currently at 989.05, reflecting a change of -1.35, or -0.14%. Despite this slight decline, the stock has shown strong performance over various periods, outperforming the benchmark Sensex in the last week, month, year-to-date, and over the past three years. Specifically, the stock has gained 6.34% over the past week, while the Sensex has decreased by 0.49%. <BR><BR>However, the stock has experienced a trend reversal, falling after six consecutive days of gains. This recent decline may be attributed to a decrease in investor participation, as evidenced by a 21.87% drop in delivery volume compared to the five-day average. Despite this, Fortis Healthcare maintains a strong position with a low Debt to EBITDA ratio of 1.67 times, indicating a solid ability to service its debt. Additionally, the company has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 70.40%. <BR><BR>The stock's liquidity remains adequate for trading, and high institutional holdings at 57.17% suggest confidence from more sophisticated investors. Overall, while the stock is currently experiencing a minor decline, its historical performance and strong fundamentals support a positive outlook for the future.

What does Fortis Health. do?

Fortis Healthcare Ltd is a leading healthcare services provider in India, with a market capitalization of INR 74,733 Cr and recent net sales of 2,365 Cr and net profit of 266 Cr as of March 2026. The company operates in the mid-cap hospital industry and has key financial metrics including a P/E ratio of 71.00 and a return on equity of 10.70%.

Overview:<BR>Fortis Healthcare Ltd is one of the largest healthcare services providers in India, operating in the hospital industry within the mid-cap market segment.<BR><BR>History:<BR>Fortis Healthcare Ltd was incorporated in an unspecified year and has established itself as a significant player in the healthcare sector. The latest quarterly results reported are for March 2026, showcasing the company's performance in terms of sales and profit.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 2,365 Cr (Quarterly Results - Mar 2026)<BR>- Most recent Net Profit: 266 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap value: INR 74,733 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 71.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.10%<BR>- Debt Equity: 0.29<BR>- Return on Equity: 10.70%<BR>- Price to Book: 7.55<BR><BR>Contact Details:<BR>- Address: Fortis Hospital Sector-62, Phase-VIII Mohali Punjab : 160062<BR>- Tel: 91-172-5096001<BR>- Email: secretarial@fortishealthcare.com<BR>- Website: http://www.fortishealthcare.com

Which are the latest news on Fortis Health.?

How big is Fortis Health.?

As of 10th June, Fortis Healthcare Ltd has a market capitalization of 74,733.00 Cr and reported net sales of 9,127.84 Cr and net profit of 1,041.78 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Fortis Healthcare Ltd has a market capitalization of 74,733.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 9,127.84 Cr, while the sum of Net Profit for the same period is 1,041.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 8,916.52 Cr, and Total Assets amount to 13,376.98 Cr.

Who are in the management team of Fortis Health.?

The management team of Fortis Health includes Ashutosh Raghuvanshi (Managing Director & CEO), Ravi Rajagopal (Chairman), and several independent and non-executive directors, along with the Company Secretary, Murlee Manohar Jain. This diverse team provides governance and strategic direction for the company.

The management team of Fortis Health includes the following members:<BR><BR>1. **Ashutosh Raghuvanshi** - Managing Director & CEO<BR>2. **Ravi Rajagopal** - Chairman & Independent Director<BR>3. **Suvalaxmi Chakraborty** - Independent Director<BR>4. **Indrajit Banerjee** - Independent Director<BR>5. **Shailaja Chandra** - Independent Director<BR>6. **DILIP KADAMBI** - Non Executive Director<BR>7. **Sim Heng Joo Joe** - Non Executive Director<BR>8. **Joerg Ayrla** - Non Executive Director<BR>9. **Tomo Nagahiro** - Non Executive Director<BR>10. **Mehmet Ali Aydinlar** - Non Executive Director<BR>11. **Lim Tsin Lin** - Non Executive Director<BR>12. **Murlee Manohar Jain** - Company Secretary & Compliance Officer<BR><BR>This diverse team brings a range of expertise to the company, contributing to its governance and strategic direction.

Should I buy, sell or hold Fortis Healthcare Ltd?

Are Fortis Healthcare Ltd latest results good or bad?

Fortis Healthcare Ltd's latest results show strong profit and revenue growth, with a net profit increase of 44.57% and record quarterly revenue. However, concerns about its high valuation and low return on equity suggest investors should be cautious, leading analysts to rate the stock as a "HOLD."

Fortis Healthcare Ltd's latest results present a mixed picture. On one hand, the company reported a strong performance in Q4 FY26, with net profit increasing by 44.57% year-on-year to ₹265.85 crores and revenue growing by 17.81% to ₹2,364.67 crores, marking the highest quarterly revenue on record. Additionally, the operating margin improved to 22.51%, reflecting better cost management.<BR><BR>However, there are concerns regarding the company's premium valuation, trading at 72x trailing earnings, which is significantly above the industry average of 63x. Analysts have rated the stock as a "HOLD," indicating caution due to its high valuation despite the strong profit growth. Furthermore, the company's return on equity (ROE) remains low at 7.20%, which is below industry standards, raising questions about its capital efficiency.<BR><BR>In summary, while Fortis Healthcare has demonstrated impressive growth in profits and revenue, the high valuation and weak return ratios suggest that investors should approach with caution. The overall sentiment is that the results are good in terms of growth, but the valuation and return metrics present challenges.

Is Fortis Health. overvalued or undervalued?

As of December 4, 2025, Fortis Health is considered expensive and overvalued with a PE ratio of 66.42, higher than its peers, despite a strong YTD return of 23.12% compared to the Sensex's 9.12%.

As of 4 December 2025, the valuation grade for Fortis Health has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 66.42, an EV to EBITDA ratio of 37.50, and a Price to Book Value of 7.09. <BR><BR>In comparison to its peers, Fortis Health's PE ratio is higher than Apollo Hospitals at 61.81 and Narayana Hrudaya at 46.47, both of which are also categorized as expensive. The company's recent stock performance shows a YTD return of 23.12%, significantly outperforming the Sensex's return of 9.12% during the same period, which may indicate strong market interest despite its overvaluation.

How has been the historical performance of Fortis Health.?

Fortis Health has shown consistent growth in net sales and profitability, with net sales increasing from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, and profit after tax improving from a loss of 588.12 Cr to a profit of 797.86 Cr during the same period. The company's financial performance reflects a positive growth trajectory with rising revenues and operating profits.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health has demonstrated a steady increase in net sales, rising from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025. The total operating income has followed a similar upward trajectory, reaching 7,782.75 Cr in March 2025, compared to 4,469.36 Cr in March 2019. The company has also improved its operating profit (PBDIT), which increased from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, reflecting an operating profit margin of 20.4% in the latest fiscal year. Profit before tax has shown a positive trend, moving from a loss of 474.51 Cr in March 2019 to a profit of 995.52 Cr in March 2025. Consequently, profit after tax has also improved significantly, from a loss of 588.12 Cr in March 2019 to a profit of 797.86 Cr in March 2025. The company's total assets have increased from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, while total liabilities have also risen, indicating a growing business scale. Cash flow from operating activities has improved, reaching 1,423.00 Cr in March 2025, although the company experienced a net cash outflow of 69.00 Cr in the same period. Overall, Fortis Health's financial performance reflects a positive growth trajectory with increasing revenues and profitability over the years.

How has been the historical performance of Fortis Health.?

Fortis Health has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 4,469.36 Cr to 7,782.75 Cr and profit after tax rising from a loss of 588.12 Cr to 797.86 Cr. The company has demonstrated a strong recovery, with significant improvements in operating profit and cash flow during this period.

Answer:<BR>The historical performance of Fortis Health shows a consistent growth trajectory in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Fortis Health's net sales have steadily increased from 4,469.36 Cr in March 2019 to 7,782.75 Cr in March 2025, reflecting a robust growth trend. The total operating income followed a similar pattern, rising from 4,469.36 Cr to 7,782.75 Cr during the same period. The operating profit (PBDIT) also demonstrated significant improvement, increasing from 317.62 Cr in March 2019 to 1,654.88 Cr in March 2025, with an operating profit margin that improved from 5.04% to 20.4%. Profit before tax reached 995.52 Cr in March 2025, up from a loss of 474.51 Cr in March 2019, while profit after tax rose to 797.86 Cr from a loss of 588.12 Cr in March 2019. The consolidated net profit has shown a positive trend, increasing from -298.93 Cr in March 2019 to 774.21 Cr in March 2025. The company's total assets have grown from 10,954.94 Cr in March 2020 to 13,376.98 Cr in March 2025, and total liabilities increased from 10,954.94 Cr to 13,376.98 Cr during the same period. Cash flow from operating activities improved significantly, reaching 1,423.00 Cr in March 2025 compared to 171.00 Cr in March 2020. Overall, Fortis Health has demonstrated a strong recovery and growth in financial performance over the years.

Is Fortis Health. technically bullish or bearish?

As of November 4, 2025, Fortis Health's technical trend is mildly bullish, supported by positive MACD and moving averages, though caution is advised due to mixed signals from the weekly KST and Dow Theory.

As of 4 November 2025, the technical trend for Fortis Health has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the weekly KST is mildly bearish, and the Dow Theory shows a mildly bearish signal on the weekly timeframe, suggesting some caution. The Bollinger Bands indicate a mildly bullish outlook on both weekly and monthly timeframes. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from KST and Dow Theory.

Who are the top shareholders of the Fortis Health.?

The top shareholders of Fortis Health include promoters holding 31.17%, mutual funds with 25.77%, and foreign institutional investors (FIIs) at 27.4%. HDFC Mutual Fund is the largest public shareholder, owning 6%, while individual investors hold 10.22%.

The top shareholders of Fortis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Northern Tk Venture Pte. Ltd. holding the highest stake at 31.17%. Mutual funds collectively hold 25.77% of the shares through 27 schemes, while FIIs own 27.4% of the company through 389 different investors. The highest public shareholder is HDFC Mutual Fund, specifically through the HDFC S&P BSE 500 ETF, which holds 6%. Additionally, individual investors account for 10.22% of the shareholding.

When is the next results date for Fortis Health.?

No Upcoming Board Meetings

Has Fortis Health. declared dividend?

Fortis Healthcare Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of July 24, 2024. The dividend yield is 0.13%, and the company has shown significant price appreciation and total returns across various periods.

Fortis Healthcare Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 24 Jul 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 6.7%, the dividend return was 0%, resulting in a total return of 6.7%.<BR><BR>Over the past year, the price return was 71.16%, the dividend return was 0.21%, leading to a total return of 71.37%.<BR><BR>In the 2-year period, the price return was 170.94%, with a dividend return of 0.65%, culminating in a total return of 171.59%.<BR><BR>For the 3-year period, the price return was 214.91%, the dividend return was 0.87%, resulting in a total return of 215.78%.<BR><BR>In the 4-year period, the price return was 236.71%, with a dividend return of 0.84%, leading to a total return of 237.55%.<BR><BR>Over the last 5 years, the price return was 548.54%, the dividend return was 1.56%, resulting in a total return of 550.1%.<BR><BR>Overall, Fortis Healthcare Ltd has declared a dividend while also demonstrating significant price appreciation over the years, with total returns reflecting strong performance across all periods. The dividend yield remains modest, indicating that the company is focusing on growth alongside returning value to shareholders.

Who are the peers of the Fortis Health.?

Fortis Health's peers include Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Fortis Health has good management risk and growth, with a 1-year return of 60.01%, lower than Krishna Institute's 85.47%.

Peers: The peers of Fortis Health are Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, and Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, Jupiter Life Lin, and the rest. Good management risk is found at Fortis Health. Average management risk is present at Aster DM Health. Excellent growth is noted at Max Healthcare and Apollo Hospitals, while good growth is observed at Fortis Health, Narayana Hrudaya, and Dr Agarwal's Hea. Below average growth is seen at Aster DM Health and Krishna Institu, and the rest. Excellent capital structure is noted at Max Healthcare, Global Health, Krishna Institu, and the rest, while good capital structure is found at Fortis Health, Narayana Hrudaya, Rainbow Child, and Dr Agarwal's Hea. Average capital structure is present at Apollo Hospitals and Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu at 85.47%, while the lowest is Dr Agarwal's Hea with no available data. Fortis Health's 1-year return is 60.01%, which is significantly higher than Dr Agarwal's Hea but lower than Krishna Institu. Additionally, Aster DM Health and Dr Agarwal's Hea have negative six-month returns.